News & media

Latest news

Women Health Segment: Why is Adalvo a partner of choice?

19 May 2022
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing our women health portfolio, and our intention is to assist our partners with the different challenges that mature products may present.

Adalvo announces DCP approval for Enzalutamide Soft Gel capsules

11 May 2022
Adalvo is delighted to announce the successful EU DCP closure of our Enzalutamide Soft Gel Capsules. We believe to be the first Company to receive an EU approval,  and with this positive news, as soon as regulatory exclusivities and patents will expire, we will proceed to launch this product.

A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen Shares in Adalvo

10 May 2022
The Consortium jointly, through Aztiq II HoldCo, has acquired a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholder in Adalvo. The Consortium’s collective industry experience, geographical reach, and commitment to sustainable development, creates a unique alliance of investors and leaders, with the financial strength to support the continuous development of the company.

Adalvo advances in diabetes space, offering injectable and oral treatment alternatives

28 April 2022
Adalvo is one of the few companies who can offer a comprehensive diabetes portfolio covering small molecule oral treatments and complex peptide injectables. We understand that diabetes is becoming one of the fast-growing diseases, and we are focusing our attention on this domain, in order to satisfy the growing patient need for these products.

Adalvo Wins the Most Innovative B2B Pharmaceutical Company, 2022 (Europe) Award

21 April 2022
We are humbled and honored to have been recognized by Global Health and Pharma Magazine's 2022 Global Excellence Awards and have been awarded the title of Most Innovative B2B Pharmaceutical Company, 2022 - Europe

Adalvo aims to launch Gabapentin ER, a branded value-added product, in Q1 2023.

19 April 2022
We are proud to announce that our distinguished hybrid / 505(b)(2) asset Gralise® has reached an advanced stage and that Adalvo will move into launch in Q1 2023.

Dalbavancin: Dossier Readiness In Q4 2022

13 April 2022
As we strengthen our injection product pipeline, we are pleased to provide a status update on our development of Dalbavancin. The development of this complex niche generic is progressing very well. Both our EU and US dossiers will be complete by Q4 2022 and we will progress with filing in early 2023.

Adalvo advances in Dermatology space with a basket of specialty products

08 April 2022
As we continue to deliver on our brand promise of being the preferred partner and setting a new standard for the future of Pharma, Adalvo provides various solutions and differentiated portfolio offerings to our partners adding a basket of interesting dermatology products, to our ever-growing portfolio offering.

Adalvo announces DCP submission date for Vortioxetine Film-Coated Tablets

05 April 2022
Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked and the submission will be completed in July 2022.

Adalvo announces successful Pivotal BE outcome of Apremilast

29 March 2022
We are pleased to announce that we have now completed our Pivotal BE program for Apremilast Film-Coated Tablets. This product has been developed in collaboration with one of our strategic partners.

Eribulin: DCP slot booked for August 2022

23 March 2022
We are pleased to provide a status update on our development of Eribulin injection 0.44mg/ml. The development of this product is progressing very well; our dossier will be available for dossier audit in May/June and a DCP slot has been booked for August 2022.

Adalvo announces successful Pivotal BE outcome of Midostaurin Capsules 25mg

17 March 2022
We are pleased to announce that, following the successful completion of our ANDA for Midostaurin Capsules 25mg in the US, we have now completed our Pivotal BE program in Europe. We will proceed with dossier filing, upon exclusivity expiry in Europe.

Adalvo announces US dossier readiness of Semaglutide 1.34mg/ml pre-filled pen

15 March 2022
We are pleased to announce that our US dossier of Semaglutide 1.34mg/ml pre-filled pen is ready and available for licensing in Ex-US markets. We will now move full steam ahead to complete our EU dossier and prepare for an EU submission.

Adalvo announces commencement of DCP procedure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet

09 March 2022
Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst the first companies to launch this product on the market in EU.

Adalvo partners with SK Pharma to create Arphio, a new business entity dedicated solely to orphan and rare disease medicines

28 February 2022
Adalvo is thrilled to announce the recent establishment of a new entity ArphioTM a venture initiated in close collaboration with SK Pharma.

Adalvo Announces Successful Pivotal BE Outcome For Apixaban 5mg Film Coated Tablets

22 February 2022
Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.

CellResearch Corporation (CRC) has been awarded SME Designation by the European Medicines Agency (EMA)

17 February 2022
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines Agency (EMA) has granted CRC the SME designation (SME).

Adalvo announces successful launch of Icatibant

27 January 2022
Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to our partners.

Adalvo announces successful pivotal BE outcome for Vortioxetine Film-Coated Tablets

05 January 2022
As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.

Adalvo enters into strategic collaboration deal with Naari Pharma

07 December 2021
Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.

Brand Assets

Adalvo logo, white on red

Adalvo logo, red on white

Adalvo logo, dark grey

Media Contact

Elisabet Hjaltadottir
Corporate Marketing & Communication